Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA

https://www.patientpower.info/video/chronic-mye...

https://www.patientpower.info/video/chronic-myelogenous-leukemia/whats-new-in-cml-treatment-tkis-asciminib-and-long-term-care
June 2
 · 
Reactions
MyMyelomaTeam

There's a lot of exciting progress happening in myeloma treatment right now! Here's a breakdown of the key advances:

CAR T-Cell Therapy
CAR T-cell therapy re-engineers your own immune cells to find and destroy myeloma cells. Two approved options are:
- Idecabtagene vicleucel (Abecma)
- Ciltacabtagene autoleucel (Carvykti)

Show Full Answer

There's a lot of exciting progress happening in myeloma treatment right now! Here's a breakdown of the key advances:

CAR T-Cell Therapy
CAR T-cell therapy re-engineers your own immune cells to find and destroy myeloma cells. Two approved options are:
- Idecabtagene vicleucel (Abecma)
- Ciltacabtagene autoleucel (Carvykti)

Carvykti has shown a 45% reduction in risk of death for people whose myeloma stopped responding to lenalidomide and at least one other treatment. Both are available after other treatments have stopped working. Bispecific T-Cell Engagers (BiTEs)
These are newer immunotherapy drugs that bind to two targets at once, helping your immune system attack myeloma cells. Approved BiTEs include:
- Teclistamab (Tecvayli)
- Talquetamab (Talvey)
- Elranatamab (Elrexfio)
- Linvoseltamab (Lynozyfic) Antibody-Drug Conjugates (ADCs)
Belantamab mafodotin (Blenrep) was reapproved in 2025 in combination with bortezomib and dexamethasone for relapsed or refractory myeloma after at least two prior treatments.

Promising Combination Therapies
A combination of talquetamab, daratumumab, and pomalidomide showed an 82% response rate in relapsed or hard-to-treat myeloma. The field is moving fast, and survival rates have improved significantly — from 35% five-year survival in 1998 to 58% more recently, with today's patients likely doing even better.

Talking with your oncologist about which of these options might suit your specific situation is always a great next step. Clinical trials are also worth exploring for access to the very latest therapies.

June 2
A MyMyelomaTeam Member

I'm currently on Talvey and Dara and have been MRD Negative since 1-2-2024.

June 3
A MyMyelomaTeam Member

@A MyMyelomaTeam Member So maybe I have to take a trip to Washington. Two +years, MRD negative!!! It must be the water!
🤣😉
All kidding aside, I definitely want to catch a Mariners game. That is a beautiful ballpark.

June 3
A MyMyelomaTeam Member

Thank you Nick!
I’ll check it out.

June 3
A MyMyelomaTeam Member

Iberdomide combined with daratumumab and dexamethasone has shown promising results in trials.
Faspro (daratumumab) does cause eye issues, I had inflammation of my eyelids when taking it with velcade and lenalidomide, pre-sct.

EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma - PubMed https://share.google/qxZMpiLoWFQx1fz7a

EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma - PubMed
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma - PubMed
June 3

Related Questions

View All
A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA

A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA